Endovascular stroke trials: why we must enroll all eligible patients.
From the Department of Radiology and Clinical Neurosciences, University of Calgary, AB, Canada (M.G., B.K.M., A.D., M.D.H.); Department of Medicine, University of Ottawa, ON, Canada (M.S.); Comprehensive Stroke Center and Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles (J.L.S.); Department of Neurology, University Hospital Essen, Germany (H.-C.D.); Department of Neurosurgery, Vanderbilt University, Nashville, TN (J.M.); University Hospital of Geneva, Switzerland (V.M.P.); Department of Neurology, UPMC Stroke Institute, Pittsburgh, PA (T.G.J.); Medical College of Wisconsin and Froedtert Hospital, Milwaukee, WI (O.Z.); Department of Neurosurgery, SUNY at Buffalo, NY (E.I.L.); and Departament de Neurociències, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain (A.D.).
Mayank
M
Goyal
Michel
M
Shamy
Bijoy K
BK
Menon
Jeffrey L
JL
Saver
Hans-Christoph
HC
Diener
J
J
Mocco
Vitor Mendes
VM
Pereira
Tudor G
TG
Jovin
Osama
O
Zaidat
Elad I
EI
Levy
Antoni
A
Davalos
Andrew
A
Demchuk
Michael D
MD
Hill
D002986:Clinical Trials as Topic; D057510:Endovascular Procedures; D004992:Ethics, Medical; D032984:Ethics, Research; D006801:Humans; D018579:Patient Selection; D020521:Stroke / Q000188:drug therapy / Q000628:therapy*; D015912:Thrombolytic Therapy
acute stroke; endovascular stroke treatment; ethics; ran domized controlled trials; trial enrollment